Majority Of Wyeth Growth Pegged To Licensed Biotech Products, Execs Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Half of big pharma’s developmental pipeline should come from outside innovators, Wyeth BioPharma’s Redmund says.